Drugs.com - Clinical Trials

Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia

Ingelheim, Germany, January 16, 2025 - Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were not...

Feb 9, 2025 - 21:44
 0
Boehringer Provides Update on Iclepertin Phase III Program in Schizophrenia
Ingelheim, Germany, January 16, 2025 - Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were not...
Read More

Tags:

Previous Article

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treat...

Next Article

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to ...

Related Posts

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Adicet Bio Receives FDA Fast Track Designation for ADI-...

Feb 9, 2025  0

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

Adaptimmune Announces U.S. FDA Breakthrough Therapy Des...

Feb 9, 2025  0

Nipocalimab Granted U.S. FDA Priority Review for the Treatment of Generalized Myasthenia Gravis

Nipocalimab Granted U.S. FDA Priority Review for the Tr...

Feb 9, 2025  0